US6048515A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Iron-containing nanoparticles with double coating and their use in diagnosis and therapy
Assignee: Freie Universität Berlin
•
Filing: 1995-07-10
•
Granted: 2000-04-11
•
Expires: 2015-07-10
Abstract
Abstract PCT No. PCT/DE95/00924 Sec. 371 Date Jun. 25, 1997 Sec. 102(e) Date Jun. 25, 1997 PCT Filed Jul. 10, 1995 PCT Pub. No. WO96/04017 PCT Pub. Date Feb. 15, 1996Modular iron-containing nanoparticles are disclosed, as well as their production and use in diagnosis and therapy. The nanoparticles are characterised in that they have an iron-containing core, a primary coat (synthetic polymer) and a secondary coat (target polymer), and optional auxiliary pharmaceutical substances, pharmaceuticals and/or adsorption mediators.
Inventors
- 👤 Mayk Kresse
- 👤 Detlev Pfefferer
- 👤 Rudiger Lawaczek
- 👤 Susanne Wagner
- 👤 Wolfgang Ebert
- 👤 Volker Elste
- 👤 Wolfhard Semmler
- 👤 Matthias Taupitz
- 👤 Josef Gaida
- 👤 Anja Herrmann
- 👤 Monika Jukl
- 👤 Udo Swiderski
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 21:17
CPC Classifications
A; A61; A61K; A61K49/00; A61K9/00; A61K9/48; A61K9/50; A61K9/51; A61K9/5107; A61K9/5115; A61K47/00; A61K47/50; A61K49/06; A61K49/18; A61K49/1818; A61K49/1821; A61K49/1824; A61K49/1827; A61K49/1851; A61K49/1863; A61K49/1866; A61K9/5094; A61K9/513; A61K9/5161; B; B01; B01J; B01J13/00; B01J13/02; B82; B82Y; B82Y5/00; G; G01; G01N; G01N2400/00; G01N2400/10; G01N2400/12; G01N2400/14; G01N2400/22; G01N2446/00; G01N2446/20; G01N2446/30
Claims Analysis
Total Claims: 30
Claim 1
Independent Claim
76 words
A nanoparticle compound for use in diagnosis and therapy, the nanoparticle compound comprising: an iron-containing core comprising iron material selected from the group consisting of magnetite and maghemite; a synthesis polymer coating the iron-containing core, the synthesis polymer selected from the group consisting of dextrans and derivatives of dextrans; and a targeting polymer non-covalently bonded to, and enveloping, the synthesis polymer to form a second coating, wherein the targeting polymer is not exposed to synthesis conditions.
Claim 2
Dependent Claim
76 words
A nanoparticle compound for use in diagnosis and therapy, the nanoparticle compound comprising: an iron-containing core comprising iron material selected from the group consisting of magnetite and maghemite; a synthesis polymer coating the iron-containing core, the synthesis polymer selected from the group consisting of dextrans and derivatives of dextrans; and a targeting polymer non-covalently bonded to, and enveloping, the synthesis polymer to form a second coating, wherein the targeting polymer is not exposed to synthesis conditions.
Claim 3
Dependent Claim
20 words
The nanoparticle compound according to claim 1 wherein the iron-containing core comprises 0.1 to 25% weight of non-iron metallic ions.
Claim 4
Dependent Claim
24 words
The nanoparticle compound according to claim 2 wherein the non-iron metallic ions are selected from the group consisting of paramagnetic ions and diamagnetic ions.
Claim 5
Dependent Claim
23 words
The nanoparticle compound according to claim 1 wherein the iron-containing core and the synthesis polymer coating have a diameter less than 100 nanometers.
Claim 6
Dependent Claim
26 words
The nanoparticle compound according to claim 1 wherein the nanoparticle compound has a hydrodynamic diameter of less than 10 times the diameter of the iron-containing core.
Claim 7
Dependent Claim
29 words
The nanoparticle compound according to claim 2 wherein the targeting polymer has a weight that is between 0.5 times to 50 times the weight of the non-iron metallic ions.
Claim 8
Dependent Claim
25 words
The nanoparticle compound according to claim 1 further comprising an optional absorption permitting peptide substance selected from the group consisting of RRTVKHHVN, RRSRHH and RSKRGR.
Claim 9
Dependent Claim
13 words
The nanoparticle compound according to claim 1 further comprising a pharmaceutically active compound.
Claim 10
Dependent Claim
26 words
The nanoparticle compound according to claim 1 wherein the targeting polymer is selected from the group consisting of dextran, dextran derivatives, laminarin, transferrin, and endothelin-receptor-specific heptapeptide.
Claim 11
Independent Claim
129 words
A method for the fabrication of a nanoparticle compound for use in diagnosis and therapy, the method comprising: mixing an iron-containing compound with a synthesis polymer in the presence of a base to create a first mixture, the synthesis polymer selected from the group consisting of dextran and derivatives of dextran; subjecting the first mixture to desorption to create a second mixture with an iron-containing core and a synthesis polymer coating, the second mixture having a polymer to iron weight ratio of 0.1:1; and non-covalently bonding a targeting polymer to the second mixture to create a nanoparticle compound comprising the iron-containing core surrounded by the synthesis polymer coating which is surrounded and enveloped by the targeting polymer coating, wherein the targeting polymer coating is not exposed to synthesis conditions.
Claim 12
Independent Claim
129 words
A method for the fabrication of a nanoparticle compound for use in diagnosis and therapy, the method comprising: mixing an iron-containing compound with a synthesis polymer in the presence of a base to create a first mixture, the synthesis polymer selected from the group consisting of dextran and derivatives of dextran; subjecting the first mixture to desorption to create a second mixture with an iron-containing core and a synthesis polymer coating, the second mixture having a polymer to iron weight ratio of 0.1:1; and non-covalently bonding a targeting polymer to the second mixture to create a nanoparticle compound comprising the iron-containing core surrounded by the synthesis polymer coating which is surrounded and enveloped by the targeting polymer coating, wherein the targeting polymer coating is not exposed to synthesis conditions.
Claim 13
Dependent Claim
34 words
The method according to claim 10 further comprising mixing an iron(II) salt and an iron(III) salt to produce the iron-containing compound with the ratio of divalent to trivalent iron being between 1:1 and 1:20.
Claim 14
Dependent Claim
40 words
The method according to claim 10 further comprising reacting an iron(III) salt mixture with a reducing agent to produce the iron-containing compound while selecting the quantity of reducing agent that generates an iron(II) to iron(III) ratio between 1:1 and 1:20.
Claim 15
Dependent Claim
19 words
The method according to claim 10 wherein the base is a 0.1:10N base used to precipitate the iron compounds.
Claim 16
Dependent Claim
29 words
The method according to claim 10 wherein the base is selected from the group consisting of ammonia gas, ammonia salt, an amine, an amine derivative and a volatile buffer.
Claim 17
Dependent Claim
19 words
The method according to claim 10 wherein the iron-containing core comprises 0.1 to 25% weight of non-iron metallic ions.
Claim 18
Dependent Claim
23 words
The method according to claim 15 wherein the non-iron metallic ions are selected from the group consisting of paramagnetic ions and diamagnetic ions.
Claim 19
Dependent Claim
22 words
The method according to claim 10 wherein the iron-containing core and the synthesis polymer coating have a diameter less than 100 nanometers.
Claim 20
Dependent Claim
25 words
The method according to claim 10 wherein the nanoparticle compound has a hydrodynamic diameter of less than 10 times the diameter of the iron-containing core.
Claim 21
Dependent Claim
28 words
The method according to claim 15 wherein the targeting polymer has a weight that is between 0.5 times to 50 times the weight of the non-iron metallic ions.
Claim 22
Dependent Claim
31 words
The method according to claim 10 further comprising adding an optional absorption permitting peptide substance selected from the group consisting of RRTVKHHVN, RRSRHH and RSKRGR, prior to adding the targeting polymer.
Claim 23
Dependent Claim
19 words
The method according to claim 10 further comprising adding a pharmaceutically active compound prior to adding the targeting polymer.
Claim 24
Dependent Claim
25 words
The method according to claim 10 wherein the targeting polymer is selected from the group consisting of dextran, dextran derivatives, laminarin, transferrin, and endothelin-receptor-specific heptapeptide.
Claim 25
Dependent Claim
104 words
A nanoparticle compound for use in diagnosis and therapy, the nanoparticle compound comprising: an iron-containing core comprising: an iron compound selected from the group consisting of magnetite and maghemite, and a plurality of non-iron metallic ions; a synthesis polymer coating the iron-containing core, the synthesis polymer having a weight ratio of 0.1 to 1.0 to the iron compound; and a targeting polymer non-covalently bonded to, and enveloping, the synthesis polymer to form a second coating, wherein the targeting polymer is not subject to synthesis conditions and has a weight that is between 0.5 times to 50 times the weight of the non-iron metallic ions.
Claim 26
Dependent Claim
104 words
A nanoparticle compound for use in diagnosis and therapy, the nanoparticle compound comprising: an iron-containing core comprising: an iron compound selected from the group consisting of magnetite and maghemite, and a plurality of non-iron metallic ions; a synthesis polymer coating the iron-containing core, the synthesis polymer having a weight ratio of 0.1 to 1.0 to the iron compound; and a targeting polymer non-covalently bonded to, and enveloping, the synthesis polymer to form a second coating, wherein the targeting polymer is not subject to synthesis conditions and has a weight that is between 0.5 times to 50 times the weight of the non-iron metallic ions.
Claim 27
Dependent Claim
26 words
The nanoparticle compound according to claim 23 wherein the targeting polymer is selected from the group consisting of dextran, dextran derivatives, laminarin, transferrin, and endothelin-receptor-specific heptapeptide.
Claim 28
Dependent Claim
19 words
The nanoparticle compound according to claim 23 wherein the synthesis polymer has a molecular weight smaller than 100,000 Da.
Claim 29
Dependent Claim
23 words
The nanoparticle compound according to claim 23 wherein the synthesis polymer is selected from the group consisting of dextran and derivatives of dextran.
Claim 30
Dependent Claim
16 words
The method according to claim 10, wherein most of the synthesis polymer is removed during desorption.
References Cited (Backward Citations)
EP0150085A2
Cited
EP0184899A1
Cited
US5720939A
Cited
US5352432A
Cited
US5262176A
Cited
US5679323A
Cited
WO1988000060A1
Cited
US5160725A
Cited
US5395688A
Cited
US5622686A
Cited
US5393525A
Cited
US5658550A
Cited
US5328681A
Cited
US5792445A
Cited
EP0516252A2
Cited
US5424419A
Cited
US5766572A
Cited
WO1994004197A1
Cited
US5349957A
Cited
US5512268A
Cited
EP0634174A1
Cited
US5411730A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-04-11 | 2003-10-11 | 2004-04-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-04-11 | 2007-10-11 | 2008-04-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-04-11 | 2011-10-11 | 2012-04-11 | $7700.00 | Window Closed / Lapsed |